The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

aragonpharm.com

Executives

4

Board of Directors

3

Aragon Pharmaceuticals Board of Directors

3 Board of directors

Aragon Pharmaceuticals has 3 board of directors, including Carl Gordon.

Name

Firm

Work History

Other Seats

Carl Gordon

Carl is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. He currently serves on the boards of directors of several public and private companies. Carl received a BA in Chemistry from Harvard College and a PhD in Molecular Biology from the Massachusetts Institute of Technology, and he was a Fellow at The Rockefeller University.

Aragon Pharmaceuticals

Leo Guthart

Leo Guthart founded Topspin in 2000. Prior to Topspin, he served as Vice Chairman of Pittway Corporation and Chief Executive Officer of its Security Group of companies, including Ademco, up until it was sold to Honeywell in 2000. After Pittway’s sale to Honeywell, he served as Chairman of the Security and Fire Solutions Group of Honeywell International. He was also Chairman of publicly-held Cylink Corporation, a leading U.S. supplier of encryption equipment that was sold to SafeNet Inc. Leo currently serves as a Director of AptarGroup, Inc. (NYSE: ATR), an international producer of dispensing valves, pumps, and closures for pharmaceuticals and perfumes. Leo is a graduate of Harvard College where he received a BA degree in Physics in 1958, and of Harvard Business School where he was a George F. Baker Scholar and received both an MBA in 1960 and a Doctorate in Business Administration with a specialty in Corporate Finance in 1966.

Aragon Pharmaceuticals

Peter Svennilson

Peter Svennilson has served as a member of our board of directors since September 2019. Mr. Svennilson also previously served as a member of our board of directors from October 2017 to April 2019. Mr. Svennilson serves as a managing partner of The Column Group, a biotechnology venture capital firm which he founded in February 2007. Mr. Svennilson served as the president and chief executive officer at ORIC Pharmaceuticals, Inc. from June 2015 to November 2015. Prior to founding The Column Group, he founded Three Crowns Capital, where he served as its managing partner from June 1996 to February 2007. Mr. Svennilson serves on the board of directors of ORIC. Mr. Svennilson previously served on the boards of directors of NGM Biopharmaceuticals, Inc. from January 2008 to May 2020, Gristone Oncology, Inc. from September 2015 to September 2019, Constellation Pharmaceuticals, Inc. from June 2016 to June 2019 and Immune Design Corp. from 2014 to August 2018. Mr. Svennilson is currently a trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received a B.S. and M.B.A. from the Stockholm School of Economics and Finance.

Aragon Pharmaceuticals

Name

Carl Gordon

Leo Guthart

Peter Svennilson

Firm

Work History

Carl is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. He currently serves on the boards of directors of several public and private companies. Carl received a BA in Chemistry from Harvard College and a PhD in Molecular Biology from the Massachusetts Institute of Technology, and he was a Fellow at The Rockefeller University.

Leo Guthart founded Topspin in 2000. Prior to Topspin, he served as Vice Chairman of Pittway Corporation and Chief Executive Officer of its Security Group of companies, including Ademco, up until it was sold to Honeywell in 2000. After Pittway’s sale to Honeywell, he served as Chairman of the Security and Fire Solutions Group of Honeywell International. He was also Chairman of publicly-held Cylink Corporation, a leading U.S. supplier of encryption equipment that was sold to SafeNet Inc. Leo currently serves as a Director of AptarGroup, Inc. (NYSE: ATR), an international producer of dispensing valves, pumps, and closures for pharmaceuticals and perfumes. Leo is a graduate of Harvard College where he received a BA degree in Physics in 1958, and of Harvard Business School where he was a George F. Baker Scholar and received both an MBA in 1960 and a Doctorate in Business Administration with a specialty in Corporate Finance in 1966.

Peter Svennilson has served as a member of our board of directors since September 2019. Mr. Svennilson also previously served as a member of our board of directors from October 2017 to April 2019. Mr. Svennilson serves as a managing partner of The Column Group, a biotechnology venture capital firm which he founded in February 2007. Mr. Svennilson served as the president and chief executive officer at ORIC Pharmaceuticals, Inc. from June 2015 to November 2015. Prior to founding The Column Group, he founded Three Crowns Capital, where he served as its managing partner from June 1996 to February 2007. Mr. Svennilson serves on the board of directors of ORIC. Mr. Svennilson previously served on the boards of directors of NGM Biopharmaceuticals, Inc. from January 2008 to May 2020, Gristone Oncology, Inc. from September 2015 to September 2019, Constellation Pharmaceuticals, Inc. from June 2016 to June 2019 and Immune Design Corp. from 2014 to August 2018. Mr. Svennilson is currently a trustee for The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received a B.S. and M.B.A. from the Stockholm School of Economics and Finance.

Other Seats

Aragon Pharmaceuticals

Aragon Pharmaceuticals

Aragon Pharmaceuticals

Aragon Pharmaceuticals Management Team

4 Team Members

Aragon Pharmaceuticals has 4 executives. Aragon Pharmaceuticals's current Chief Medical Officer is Isan Chen.

Name

Work History

Title

Status

Isan Chen

Chief Medical Officer

Current

Richard A Heyman

President

Former

Paul B Cleveland

Chief Financial Officer, Executive Vice President

Former

Dennis Hester

Senior Director

Former

Name

Isan Chen

Richard A Heyman

Paul B Cleveland

Dennis Hester

Work History

Title

Chief Medical Officer

President

Chief Financial Officer, Executive Vice President

Senior Director

Status

Current

Former

Former

Former

You May Also Like

Can-Fite BioPharma Logo
Can-Fite BioPharma

Can-Fite BioPharma is a biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities.

M
Metronome Therapeutics

Metronome Therapeutics is developing oncology drugs

A
AnaMar Medical

AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.

I
Inimex Pharmaceuticals

Inimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR products will also benefit healthcare payors by reducing costs associated with hospitalization. Inimex' lead IDR product IMX942 targets a broad spectrum of life-threatening hospital infections, many of which are caused by antibiotic-resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant Enterococcus (VRE). IMX942 is active against both normal and drug-resistant bacteria and its ability to stimulate host innate immune defenses is not susceptible to bacterial antibiotic resistance mechanisms. The first clinical indication for IMX942 will be the prevention of infections associated with cancer chemotherapy-induced immune suppression. nnAdditional IDR product candidates will be developed for distinct disease areas, with an emphasis on inflammatory disease and demonstration of the potential for orally available IDR dosage forms.

L
Locus Pharmaceuticals

Locus Pharmaceuticals is a privately held pharmaceutical company focused on developing small molecule therapeutic drugs to address unmet medical needs. The company's core technology is a fragment-based, computational approach, which Locus has combinated with highly integrated medicinal chemistry, crystallography and biology capabilities to create a unique drug design and development platform.

M
MuriGen

MuriGen is building a portfolio of drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.